Enjoy complimentary customisation on priority with our Enterprise License!
The global sinusitis drugs market size is estimated to grow by USD 801.39 million between 2022 and 2027 accelerating at a CAGR of 6.23%.
This sinusitis drugs market report extensively covers market segmentation by Product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and Geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
Sinus infections are caused by trapped fluid in the sinus glands, which can lead to the growth of germs. The CDC reports that 9 out of 10 adults and 5-7 out of 10 children in the US get sinus infections from viruses. Bacterial infections are less common, affecting 1 out of 10 adults and 3-5 out of 10 children. Allergies, pollutants, and fungal infections can also cause sinus infections. Risk factors include respiratory tract infections, sinus gland structural problems, weakened immunity or immunosuppressive drugs, and nasal polyps. To help patients fight sinus infections market players are focussing on mergers and acquisitions strategy and at the same time they are increasing the awareness of this infection.
View the Bestselling Market Research Sample
The COVID-19 pandemic had only a slight negative impact on the sinusitis drugs market in North America in 2020, despite affecting all countries, especially the US. Lockdowns and government guidelines led to limited or halted non-urgent treatments and clinical visits, causing a slight decline in sales of sinusitis drugs through offline medical stores. However, the use of e-commerce channels increased, leading to a rise in demand for sinusitis drugs online. Overall, the market witnessed a mixed impact in 2020 and Q1 2021. As pharmaceuticals were considered essential services, demand and supply were not significantly affected, and sinusitis drugs were made available through both online and offline channels. The availability of these drugs is expected to lead to market growth during the forecast period.
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Vendors in the global sinusitis drugs market are increasingly engaging in mergers and acquisitions to develop novel therapies for the treatment of sinusitis. For example, Armata Pharmaceuticals completed a merger between C3J Therapeutics and AmpliPhi Biosciences to develop bacteriophage therapeutics to combat antibiotic resistance. Knopp Biosciences is collaborating with UK medical research companies to evaluate the efficacy of its lead drug candidate, dexpramipexole, for treating severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Such efforts are expected to boost drug development activities and create opportunities for other vendors to enter the market.
Major players in the global sinusitis drugs market are investing heavily in R&D to develop new drugs for the treatment of sinusitis. LYRA THERAPEUTICS raised USD 29 million for its implant, LYR-210, which is designed using novel technologies to deliver approved steroids in the sinonasal tissues that are difficult to penetrate with traditional therapeutic options. LYR-210 is inserted into the inflamed sinonasal area, ensuring gradual release of topical steroids for six months. Phase I trials showed it was well-tolerated and effective in reducing chronic rhinosinusitis symptoms. The emergence of novel drug delivery systems and increased investments in R&D are expected to boost the consumption of sinusitis drugs and drive market growth.
The lack of development of antibiotics to fight multidrug-resistant bacteria is a major challenge for the growth of the sinusitis drugs market. Most drugs in the pipeline are modifications of existing antibiotics, and sales of antibiotics have declined due to antibiotic resistance in sinusitis patients. Major vendors such as Bayer, Merck, Novartis, Sanofi, and Pfizer have stopped investing in antibiotic research and are exiting the market. Novartis sold its three antibiotics to Boston Pharmaceuticals, and Sanofi sold its antibiotic unit to Evotec. Developing new antibiotics is expensive and time-consuming, and the commercial potential and return on investment are low due to antibiotic resistance. Overuse of prescription antibiotics is the main cause of rising resistance, hindering the development of novel antibiotics. This lack of investment in antibiotics may cause a decline in the growth of the sinusitis drugs market during the forecast period.
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbvie - The company offers sinusitis drugs such as RINVOQ (upadacitinib). Also, under this segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance globally to achieve its established long-term strategic goals.
The report also includes detailed analyses of the competitive landscape of the market and information about prominent and key market vendors, including:
Technavio’s report consists of a holistic analysis of the key development analysis, development stage, key market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
The market share growth by the steroid nasal sprays segment will be significant during the forecast period. The high market share of this segment is attributed to the therapeutic efficacy of these drugs in relieving the signs and symptoms of sinusitis. Steroid nasal sprays are used as off-label prescription drugs. They act by reducing swelling and mucus production, thus relieving the symptoms of nasal congestion and improving the drainage of fluid from the sinus. However, these drugs do not provide immediate relief of symptoms and may require multiple administrations to yield the desired outcome. These drugs are often used in combination with nasal wash for better outcomes in patients with sinusitis and other nasal problems. Flonase, NASACORT AQ, Nasonex, Rhinocort, Zetonna, and QNASL are some of the steroid nasal sprays available in the market. Such factors are driving market growth.
Get a detailed analysis of various segments View Sample PDF
For more insights on the market share of various regions View PDF Sample now!
North America is projected to contribute 40% of market growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market growth in this region is attributed to the increased investments in R&D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region. Also, Genentech is also engaged in conducting Phase II clinical trials on XOLAIR (omalizumab) for the treatment of nasal polyps. The successful launch of new drugs for these indications will result in a paradigm shift from small molecules to biologics and also pave the path for other vendors to enter the market, which contributes to market growth.
Sinusitis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2022 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.23% |
Market growth 2023-2027 |
USD 801.39 million |
Market structure |
Fragmented |
YoY growth (%) |
4.96 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Bayer AG, Bionpharma Inc., CHIESI Farmaceutici SpA, Cipla Ltd., Dr Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Merck and Co. Inc., Neopharma Corp., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teligent Inc., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.